Our mission: to create a sustainable present and future for cell and gene therapies, ensuring access for all patients in need.

Developed by Oneiros Care, a company founded in July 2023 in Lyon, HarmonyCell is an innovative solution designed to address the challenges of cell and gene therapies.

HarmonyCell was designed by leveraging the expertise of its founding team and the valuable insights gained from healthcare providers and pharmaceutical companies, working closely with hematology departments from leading treating centers.

HarmonyCell development follows an iterative approach grounded in solid scientific principles, enriched by research from French and European hematology societies.

Key figures

Interviews conducted
100+
Hematology departments consulted
8
Treatment journeys already available on HarmonyCell
3

The founding team

Valentin Petit

CEO

Biologist by training (Master's in Cancer Biology, University of Lyon 1) and graduate in business and entrepreneurship (MSc, HEC Paris), Valentin worked for three years as a consultant for major pharmaceutical laboratories at Executive Insight in Zurich.
It was through this experience that he discovered cell and gene therapies and their challenges.

Cyril Boyer

CTO

Digital transformation and software development specialist, Cyril was CTO at Skinny Robot in Auckland for six years, where he led the creation and commercialization of a SaaS ERP solution.
He has also held key positions at Naveya and Sloane and Moving Village, strengthening his expertise in development and technical team management.

Our scientific references

Treatment journeys available on HarmonyCell are based on recognized scientific references and have been validated by numerous hematology departments

SFGM

SFGM

Harmonization workshops1

EBMT

EBMT

Handbooks2,3 articles4,5 and JACIE standards6

MATHEC

MATHEC

MATHEC national care protocol7

References

  1. SFGM-TC. Harmonization of practices workshops. Link
  2. EBMT (2019). EBMT Handbook Hematopoietic Stem Cell Transplantation and Cellular Therapies. Link
  3. EBMT & EHA (2022). EBMT-EHA CAR-T Cell Handbook. Link
  4. Yakoub-Agha et al, (2020). Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Link
  5. P.J. Hayden et al, (2021). Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Link
  6. EBMT. 8th Edition FACT-JACIE Standards. Link
  7. HAS. PNDS – Hematopoietic Stem Cell Transplantation. Link